EPHA2 and prostate carcinoma: In the present study, in order to test the ability of EphA2 agonistic agents to reduce EphA2 levels over time, we initially treated prostate cancer PC-3 cells with 10 μM of the agonistic synthetic agent 135H12, or with the dimeric EphA2 ligand ephrinA1-Fc (at 1 μg/mL corresponding to ~22 nM of the monomer).